These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 3661762)

  • 1. Familial schizophrenia and treatment response.
    Silverman JM; Mohs RC; Davidson M; Losonczy MF; Keefe RS; Breitner JC; Sorokin JE; Davis KL
    Am J Psychiatry; 1987 Oct; 144(10):1271-6. PubMed ID: 3661762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlates of lateral ventricular size in chronic schizophrenia, I: Behavioral and treatment response measures.
    Losonczy MF; Song IS; Mohs RC; Small NA; Davidson M; Johns CA; Davis KL
    Am J Psychiatry; 1986 Aug; 143(8):976-81. PubMed ID: 3524278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of very poor outcome schizophrenia.
    Keefe RS; Mohs RC; Losonczy MF; Davidson M; Silverman JM; Kendler KS; Horvath TB; Nora R; Davis KL
    Am J Psychiatry; 1987 Jul; 144(7):889-95. PubMed ID: 3605400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lateral ventricular enlargement and clinical response in schizophrenia.
    Smith RC; Baumgartner R; Ravichandran GK; Mauldin M; Burd A; Vroulis G; Gordon J; Calderon M
    Psychiatry Res; 1985 Mar; 14(3):241-53. PubMed ID: 3858896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ventricle-brain ratio and alogia in 19 young patients with chronic negative and positive schizophrenia.
    Moscarelli M; Cesana BM; Ciussani S; Novati NC; Cazzullo CL
    Am J Psychiatry; 1989 Feb; 146(2):257-8. PubMed ID: 2912270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Premorbid sociosexual functioning and long-term outcome in schizophrenia.
    Keefe RS; Mohs RC; Losonczy MF; Davidson M; Silverman JM; Horvath TB; Davis KL
    Am J Psychiatry; 1989 Feb; 146(2):206-11. PubMed ID: 2912262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ventricular enlargement, clinical correlates and treatment outcome in chronic schizophrenic inpatients.
    Wilms G; Van Ongeval C; Baert AL; Claus A; Bollen J; De Cuyper H; Eneman M; Malfroid M; Peuskens J; Heylen S
    Acta Psychiatr Scand; 1992 Apr; 85(4):306-12. PubMed ID: 1375802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VBR in schizophrenia: relationship to family history of psychosis and season of birth.
    DeQuardo JR; Goldman M; Tandon R
    Schizophr Res; 1996 Jul; 20(3):275-85. PubMed ID: 8827854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
    Zimbroff DL; Kane JM; Tamminga CA; Daniel DG; Mack RJ; Wozniak PJ; Sebree TB; Wallin BA; Kashkin KB
    Am J Psychiatry; 1997 Jun; 154(6):782-91. PubMed ID: 9167505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early response to haloperidol treatment in chronic schizophrenia.
    Stern RG; Kahn RS; Harvey PD; Amin F; Apter SH; Hirschowitz J
    Schizophr Res; 1993 Aug; 10(2):165-71. PubMed ID: 8398949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia.
    Goldberg TE; Bigelow LB; Weinberger DR; Daniel DG; Kleinman JE
    Am J Psychiatry; 1991 Jan; 148(1):78-84. PubMed ID: 1984711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased prevalence of schizophrenia spectrum disorders in relatives of neuroleptic-nonresponsive schizophrenic patients.
    Joober R; Rouleau GA; Lal S; Bloom D; Lalonde P; Labelle A; Benkelfat C
    Schizophr Res; 2005 Sep; 77(1):35-41. PubMed ID: 16005383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensive treatment with haloperidol of treatment-resistant chronic schizophrenic patients.
    Hollister LE; Kim DY
    Am J Psychiatry; 1982 Nov; 139(11):1466-8. PubMed ID: 7137396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of response to haloperidol in schizophrenia: neuroendocrine, neuromorphological and clinical variables.
    Mauri MC; Vita A; Giobbio GM; Ferrara A; Dieci M; Bitetto A; Altamura AC
    Int Clin Psychopharmacol; 1994; 9(1):3-7. PubMed ID: 8195579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebral structural pathology in schizophrenia: evidence for a selective prefrontal cortical defect.
    Shelton RC; Karson CN; Doran AR; Pickar D; Bigelow LB; Weinberger DR
    Am J Psychiatry; 1988 Feb; 145(2):154-63. PubMed ID: 3277448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blunted change in cerebral glucose utilization after haloperidol treatment in schizophrenic patients with prominent negative symptoms.
    Wolkin A; Sanfilipo M; Duncan E; Angrist B; Wolf AP; Cooper TB; Brodie JD; Laska E; Rotrosen JP
    Am J Psychiatry; 1996 Mar; 153(3):346-54. PubMed ID: 8610821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical correlates of body weight changes in schizophrenia.
    Lawson WB; Karson CN
    J Neuropsychiatry Clin Neurosci; 1994; 6(2):187-8. PubMed ID: 8044044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RBC and plasma levels of haloperidol and clinical response in schizophrenia.
    Smith RC; Vroulis G; Shvartsburd A; Allen R; Lewis N; Schoolar JC; Chojnacki M; Johnson R
    Am J Psychiatry; 1982 Aug; 139(8):1054-6. PubMed ID: 7091432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic issues in chronic schizophrenia: kraepelinian schizophrenia, undifferentiated schizophrenia, and state-independent negative symptoms.
    Keefe RS; Lobel DS; Mohs RC; Silverman JM; Harvey PD; Davidson M; Losonczy MF; Davis KL
    Schizophr Res; 1991; 4(2):71-9. PubMed ID: 2039764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ventricular abnormalities in affective disorder: clinical and demographic correlates.
    Andreasen NC; Swayze V; Flaum M; Alliger R; Cohen G
    Am J Psychiatry; 1990 Jul; 147(7):893-900. PubMed ID: 2356874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.